D. Boral Capital analyst Jason Kolbert downgraded CorMedix (NASDAQ: CRMD) from Buy to Hold.The analyst comments "CorMedix has priced a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE